Can Avanos Medical scale into its next phase of growth targeting digestive health and non-opioid pain?
Avanos Medical's pivot to high-margin medtech matters because management reported a 2025 focus on digestive health and non-opioid pain, aiming to lift margins and shift sales toward ambulatory surgery centers.
Drive product-led growth while cutting tariff-driven supply costs; monitor successful clinical wins and margin recovery as execution signals. See Avanos SWOT Analysis for strategic detail.
Where Is Avanos Trying to Go Next?
Avanos is targeting a revenue milestone of $1,000,000,000 by 2030, up from $701,200,000 in 2025, focusing on Specialist Nutrition Systems (NICU and short-term enteral feeding), non-opioid post-surgical pain devices, and faster geographic growth in EMEA and Asia-Pacific.
Specialist Nutrition Systems: NICU and Short-term Enteral Feeding
Avanos is prioritizing its Specialist Nutrition Systems segment to capture white space in the Neonatal Intensive Care Unit market and short-term enteral feeding where higher ASPs and recurring disposables can lift margins; NICU devices and consumables are a clear route to scale revenue from the 2025 base.
Geographic Expansion: Double-digit Growth in EMEA and Asia-Pacific
With ~75% of 2025 sales concentrated in North America, management aims to reduce concentration by driving double-digit growth in EMEA and Asia-Pacific via optimized distribution, focused regulatory pathways, and localized commercial partnerships.
Product Upside: Non-opioid Pain Management and Reimbursed Pump Therapy
New 2025 US reimbursement codes under the NOPAIN Act support adoption of ON-Q and ambIT pumps for non-opioid post-surgical care, expanding unit sales and recurring ancillary revenue from disposables and service contracts.
Most Credible Next Move: Drive Adoption via Reimbursement and Provider Economics
Near-term (2025-2026) progress looks most realistic by converting hospital protocols to include reimbursed non-opioid pump therapy, where clearer reimbursement mechanics and evidenced cost savings will accelerate procurement decisions.
Where Avanos Is Trying to Go Next
Avanos outlook centers on hitting $1.0 billion by 2030 through NICU nutrition growth, scaling non-opioid pump adoption under new reimbursement, and lowering North American revenue concentration by expanding EMEA and Asia-Pacific.
- Main growth opportunity: Specialist Nutrition Systems targeting NICU and short-term enteral feeding
- Expansion potential: double-digit EMEA and Asia-Pacific growth to reduce 75% North America concentration
- Product/category upside: ON-Q and ambIT pumps plus recurring disposables and service revenue under new NOPAIN Act codes
- Most credible near-term driver: faster hospital adoption driven by 2025 reimbursement codes and demonstrated provider cost savings
See market positioning and served segments for context in this resource: Who Avanos Company Serves
Avanos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Is Avanos Building to Get There?
Avanos Medical is building structural agility and product intelligence to convert growth opportunities into results, moving neonatal syringe production to Mexico and Cambodia and expanding enteral and NICU product lines while piloting wearables and AI for higher-value care.
Expansion Priorities: Nearshoring and Market Reach
Avanos is relocating neonatal syringe production from China to Mexico and Cambodia with a mid-2026 completion target to capture USMCA benefits and cut tariff exposure. The move supports faster service to North American hospitals and strengthens global supply chain resilience.
Product or Service Innovation: Enteral and NICU Leadership
The company is scaling CORTRAK and CORGRIP 2 enteral feeding systems and integrating Nexus Medical and the TKO anti-reflux connector to deepen NICU penetration and raise ASPs for consumables and disposables.
Technology and AI Initiatives: Sensors and Nutrition AI
Avanos is piloting wearable sensor integration for pain pumps to enable remote monitoring and exploring AI-driven nutrition management for enteral therapy, targeting higher recurring software and services revenue over the 2026 horizon.
Partnerships or Acquisitions: Strategic NICU Buys
The Nexus Medical acquisition and integration of the TKO connector expand the NICU portfolio and add cross-sell channels into neonatal units, accelerating product uptake and recurring consumable sales.
Investment and Execution: Cost Transformation
A transformation program is targeting $15 to $20 million of incremental annualized savings by end-2026, funding R&D pilots and nearshoring capital without diluting margins.
Most Important Strategic Build: Supply Chain Repositioning
Nearshoring neonatal syringe production to Mexico and Cambodia is the pivotal move for 2025/2026: it reduces tariff risk, boosts gross margin leverage, and supports faster fulfillment into the U.S. NICU and acute-care market.
What It Is Building to Get There
Avanos is combining supply – chain reshaping, NICU and enteral product expansion, and digital product upgrades to push revenue toward higher-margin recurring streams and capture more hospital wallet share.
- Nearshoring neonatal syringe production to Mexico and Cambodia to leverage USMCA and reduce tariff exposure
- Scaling CORTRAK and CORGRIP 2 and integrating Nexus Medical and the TKO connector to grow enteral and NICU market share
- Piloting wearable sensors for pain pumps and exploring AI-driven nutrition management as tech-enabled upsell paths
- Delivering $15 to $20 million in annualized savings by end-2026 to fund R&D and margin expansion
Read more context in this related piece What Avanos Company Stands For
Avanos PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What Could Slow Avanos Down?
The main near-term risks for Avanos are cash-flow pressure from its China exit and transitional costs, uncertain reimbursement adoption for surgical pain products, competitive pressure from larger medtech firms, and execution risk on manufacturing shifts to Mexico.
Demand and Market Pressure
Weakening hospital procurement cycles or slower adoption of the NOPAIN Act reimbursement could blunt demand for new surgical pain offerings and slow growth for MIC-KEY gastrostomy products in the near term.
Competition and Pricing Pressure
Large peers such as Medtronic can bundle devices into large-system contracts, exerting pricing pressure and accelerating customer switching away from niche players, eroding share and margins for Avanos' specialty lines.
Execution or Investment Risk
The China exit creates immediate financial friction: management estimates a $30,000,000 tariff expense in 2026, and free cash flow fell to $43,100,000 in 2025 from $82,900,000 in 2024, tightening capital for investments and raising execution risk during the Mexico transition.
Regulation, Technology, or External Disruption
Reimbursement delays for the NOPAIN Act and potential supply-chain disruptions tied to geographic manufacturing shifts could stall commercialization; geopolitical or tariff changes would add cost volatility to Avanos' international expansion strategy.
Key Headwinds for Avanos' Growth
Avanos' outlook depends on executing a costly China exit and Mexico ramp, securing NOPAIN Act reimbursement, and defending share against larger medtech bundlers; failure on any of these fronts could materially slow the Avanos future direction and Avanos strategic plan 2026 and beyond.
- Demand and pricing pressure from hospital procurement cycles and slower NOPAIN Act adoption
- Execution risk from the China-to-Mexico transition and tightened free cash flow
- Reimbursement, tariff, and supply-chain disruptions tied to geopolitical shifts
- The single biggest risk: delayed reimbursement adoption for surgical pain products, which could derail the growth story
See operational and go-to-market context in this piece on sales approach: How Avanos Company Sells
Avanos SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Strong Does Avanos's Growth Story Look?
The growth story looks mixed but cautiously optimistic: demand in key segments is solid, yet earnings remain fragile and revenue guidance points to consolidation rather than breakout expansion.
Growth Direction: Consolidation with Tailwinds
Avanos outlook shows steady underlying demand-Specialty Nutrition Systems grew 9.2 percent in 2025-while the firm moves into a consolidation phase with 2026 revenue guided to the $700-$720 million range.
Near-Term Growth Signals: Mixed Indicators
Management reported 6 percent organic growth in strategic areas for 2025 and reiterated supply-chain migration timelines; yet a $77 million goodwill impairment in 2025 and repeated net losses temper near-term optimism.
Strategic Support for Growth: Execution-Dependent
Key strategic moves-supply chain migration, focus on non-opioid clinical advantages, and targeted portfolio actions including divestitures-could lift margins if completed by mid-2026; capital allocation appears conservative.
Upside Potential: Real but Conditional
Reaching $1 billion revenue is believable only if supply-chain migration completes by mid-2026 and clinical advantages convert into repeat, high-margin contract wins and recurring revenue growth.
Downside Risk to the Outlook: Execution and Margins
Primary risk is execution: delays in supply chain migration, failure to win sustained non-opioid contracts, or further impairments could keep margins suppressed and stall progress toward the revenue inflection.
Overall Growth Judgment: Cautiously Optimistic but Fragile
Avanos future direction is plausible for moderate expansion; the outlook depends on meeting mid-2026 operational milestones and converting product-level clinical strengths into consistent commercial wins.
How Strong the Growth Story Looks
Conclusion: the Avanos strategy points to moderate expansion with meaningful upside if execution succeeds; absent that, progress will be uneven and constrained.
- Positioning: moderate expansion, consolidation phase toward $700-$720 million revenue in 2026
- Most supportive near-term signal: 9.2 percent Specialty Nutrition Systems growth and 6 percent organic growth in strategic areas (2025)
- Biggest upside: completing supply chain migration by mid-2026 and converting non-opioid clinical advantages into repeat high-margin contracts
- Main downside risk: execution failures-supply chain delays, contract conversion shortfalls, or further goodwill/asset impairments
For context on corporate ownership and recent portfolio moves see Who Owns Avanos Company.
Avanos VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Avanos is aiming to reach $1,000,000,000 in revenue by 2030. The main drivers in the blog are Specialist Nutrition Systems, non-opioid post-surgical pain devices, and stronger growth in EMEA and Asia-Pacific to reduce North American concentration.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.